Amgen Inc. (NASDAQ:AMGN) Shares Bought by Tokio Marine Asset Management Co. Ltd.

Tokio Marine Asset Management Co. Ltd. raised its position in Amgen Inc. (NASDAQ:AMGN) by 2.1% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 15,728 shares of the medical research company’s stock after acquiring an additional 316 shares during the period. Tokio Marine Asset Management Co. Ltd.’s holdings in Amgen were worth $4,099,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in AMGN. Capital Performance Advisors LLP purchased a new position in Amgen in the third quarter valued at about $25,000. Legacy Investment Solutions LLC acquired a new position in Amgen during the third quarter worth $29,000. Matrix Trust Co purchased a new stake in Amgen during the third quarter worth $36,000. Heck Capital Advisors LLC acquired a new stake in Amgen in the fourth quarter valued at $36,000. Finally, Livelsberger Financial Advisory purchased a new position in shares of Amgen in the third quarter valued at $56,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Price Performance

AMGN stock opened at $285.42 on Monday. The company has a market capitalization of $153.42 billion, a PE ratio of 36.55, a P/E/G ratio of 2.85 and a beta of 0.56. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55. The stock’s 50 day moving average is $271.06 and its two-hundred day moving average is $304.33. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85.

Amgen Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be given a $2.38 dividend. The ex-dividend date is Friday, February 14th. This represents a $9.52 annualized dividend and a dividend yield of 3.34%. This is an increase from Amgen’s previous quarterly dividend of $2.25. Amgen’s payout ratio is presently 121.90%.

Analyst Ratings Changes

Several research firms recently commented on AMGN. Piper Sandler decreased their price objective on shares of Amgen from $344.00 to $310.00 and set an “overweight” rating on the stock in a research report on Thursday, January 2nd. Jefferies Financial Group restated a “buy” rating and set a $380.00 price objective on shares of Amgen in a report on Tuesday, November 12th. Wolfe Research started coverage on Amgen in a report on Friday, November 15th. They issued a “peer perform” rating for the company. Sanford C. Bernstein started coverage on shares of Amgen in a report on Thursday, October 17th. They issued an “outperform” rating and a $380.00 target price for the company. Finally, Citigroup cut their price target on shares of Amgen from $310.00 to $295.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $314.00.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.